Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 1,372 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube sold 1,372 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $16,710.96. Following the completion of the transaction, the chief accounting officer now directly owns 45,640 shares of the company’s stock, valued at $555,895.20. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $12.02 on Thursday. Intellia Therapeutics, Inc. has a 52-week low of $11.34 and a 52-week high of $34.87. The company has a fifty day moving average of $13.91 and a 200-day moving average of $19.15. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter in the previous year, the company earned ($1.38) earnings per share. The business’s quarterly revenue was down 24.1% on a year-over-year basis. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on NTLA. Chardan Capital raised their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Wells Fargo & Company lowered their target price on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a research note on Monday, November 18th. Canaccord Genuity Group restated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group decreased their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, William Blair reissued a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NTLA. Franklin Resources Inc. lifted its position in Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in Intellia Therapeutics by 147.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 53,590 shares of the company’s stock valued at $1,101,000 after buying an additional 31,976 shares during the last quarter. Virtu Financial LLC purchased a new stake in Intellia Therapeutics during the 3rd quarter valued at $417,000. Geode Capital Management LLC grew its holdings in Intellia Therapeutics by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after acquiring an additional 49,367 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after acquiring an additional 44,022 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.